The American Journal of Medicine
Volume 122, Issue 2, Supplement , Pages S22-S32, February 2009

Safety of Bisphosphonates in the Treatment of Osteoporosis

  • Robert R. Recker, MD

      Affiliations

    • School of Medicine, Creighton University, Omaha, Nebraska, USA
    • ,
  • E. Michael Lewiecki, MD

      Affiliations

    • New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA
    • Corresponding Author InformationRequests for reprints should be addressed to E. Michael Lewiecki, MD, New Mexico Clinical Research & Osteoporosis Center, 300 Oak Street NE, Albuquerque, New Mexico 87106
    • ,
  • Paul D. Miller, MD

      Affiliations

    • Colorado Center for Bone Research, Lakewood, Colorado, USA
    • ,
  • James Reiffel, MD

      Affiliations

    • Columbia University, New York, New York, USA

Abstract 

In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).

Keywords: Fractures, Atrial fibrillation, Renal safety, Bisphosphonate safety, Oversuppression, Healing

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)01192-3

doi:10.1016/j.amjmed.2008.12.004

The American Journal of Medicine
Volume 122, Issue 2, Supplement , Pages S22-S32, February 2009

Article Tools

* Image Usage & Resolution